Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.

Diel, Ingo J.; Kaufmann, M.; Goerner, R.; Costa, Serban Dan; Kaul, S.; Bastert, G.

doi:10.1200/jco.1992.10.10.1534

Cited by 248 publications

(82 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The proportion of tumour cell-positive patients (positive reaction with 2E1 1) of 47% (n = 132) was in the same range as in our previous studies (Diel et al, 1992(Diel et al, , 1994(Diel et al, , 1996. TCD in bone marrow correlates with prognosis in patients with primary breast cancer.…”

Section: Discussionsupporting

confidence: 76%

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

Solomayer

Diel²,

Wallwiener³

et al. 1997

Br J Cancer

Self Cite

View full text Add to dashboard Cite

SummaryPatients with an elevated level of urokinase plasminogen activator (uPA) in breast cancer tissue have an adverse prognosis. This study evaluated the prognostic relevance of uPA detection in disseminated tumour cells in bone marrow. Bone marrow was sampled intraoperatively from both iliac crests in 280 patients with primary breast cancer. Interphase cells were enhanced and stained immunocytologically with two antibodies: 2E11, which detects TAG 12 -a tumour-associated glycoprotein typically expressed by almost all breast cancer cells -and the anti-uPA antibody HD-UK9. Thirty-five of the 2E1 1-positive women (n = 132, 47%) developed metastatic disease (median follow-up time 44 months). Of these, most were uPA positive (n = 23, 65%) and only 12 were uPA negative. Patients with uPApositive cells in bone marrow (n = 98, 35%) had a significantly shorter metastasis-free interval (36 months) than women who were uPA negative (44.5 months). The worst prognosis was seen in patients positive for both markers (29.5 months), followed by those who were uPA negative and 2E11 positive (37 months). The detection of uPA on disseminated tumour cells characterizes a subgroup of patients with an even worse prognosis, who should undergo more aggressive adjuvant systemic therapy. For the first time, it was possible to evaluate an important qualitative parameter involved in the process of breast cancer metastases.

show abstract

Section: Discussionsupporting

confidence: 76%

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

Solomayer

Diel²,

Wallwiener³

et al. 1997

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Yu-Shin Hung 1 , Wen-Chi Chou 1 *, Tai-Di Chen 2 , Tse-Ching Chen 2 , Po-Nan Wang 1 , Hung Chang 1 , Hung-Chih Hsu 1 , Wen-Chi Shen 1 , Wei-Hong Cheng 3 , Jen-Shi Chen 1 * et al, 1992;Trillet-Lenoir et al, 1994;Kim et al, 2007;Kwon et al, 2011;Mehdi et al, 2011).…”

Section: Prognostic Factors In Adult Patients With Solid Cancers and mentioning

confidence: 99%

“…Therefore, only small cases series of patients with solid cancers and bone marrow metastases are reported in the literature. Among these reports, malignancies of the prostate, breast, lungs, and stomach were the primary tumors that most frequently metastasized to the bone marrow (Hansen et al, 1971;Shah et al, 1985;Ceci et al, 1988;Tritz et al, 1989;Diel …”

Section: Introductionmentioning

confidence: 99%

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Hung¹,

Chou²,

Chen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Solid cancers with bone marrow metastases are rare but lethal. This study aimed to identify clinical factors predictive of survival in adult patients with solid cancers and bone marrow metastases. Methods: A total of 83 patients were enrolled consecutively between January 1, 2000 and December 31, 2012. Bone marrow metastases were confirmed by biopsies. Patient clinical features and laboratory data were analyzed for associations. Results: The median age of the patients was 54 years (range, 23-88 years), and 58% were male. The 3 most common primary tumor locations were the stomach (32 patients, 39%), prostate (16 patients, 19%), and lungs (12 patients, 15%). The median overall survival was 49 days (range, 3-1423 days). Patients with Eastern Cooperative Oncology Group performance status 1, cancers of prostate origin, platelet counts over 50,000/ml, and undergoing antitumor therapies had a significantly better prognosis in the multivariate analysis. The median survival times were 173 and 33 days for patients with 2-3 more favorable parameters (n=24) and those with 0-1 (n=69), respectively (hazard ratio 0.30; 95% CI 0.17-0.52, p<0.001). Conclusions: Solid cancers with bone marrow metastases are dismal and incurable diseases. Understanding prognostic factors to these diseases helps medical personnel to provide appropriate treatments and better inform patients about outcomes. Antitumor therapies may improve outcomes in selected patient cohorts.

show abstract

“…Various techniques, including morphology, flow cytometry and cytogenetics, have been used to detect disseminated tumour cells, but most of these have limited sensitivity and specificity (Frank et al, 1990;Diel et al, 1992;Johnson et al, 1995) and are time-consuming (Gross et al, 1995). Immunocytochemistry has also been used in an attempt to detect circulating breast carcinoma cells perioperatively, but sensitivity remains a concern with this technique (McCulloch et al, 1995;Choy and McCulloch, 1996).…”

mentioning

confidence: 99%

Putative markers for the detection of breast carcinoma cells in blood

El-Tahir

Mallinson²,

Birnie³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary The aim of this study was to investigate certain genes for their suitability as molecular markers for detection of breast carcinoma cells using the reverse transcriptase-polymerase chain reaction (RT-PCR). RNA was prepared from MCF-7 breast carcinoma cells and peripheral blood leucocytes of healthy female volunteers. This RNA was screened for mRNA of MUC1, cytokeratin 19 (CK19) and CD44 (exons 8-11) by RT-PCR and the results validated by Southern blots. Variable degrees of expression of MUC1 and CD44 (exons 5-11) were detected in normal peripheral blood, rendering these genes non-specific for epithelial cells and therefore unsuitable for use as markers to detect breast carcinoma cells. Although CK1 9 mRNA was apparently specific, it was deemed unsuitable for use as a marker of breast cancer cells in light of its limited sensitivity. Furthermore, an attempt at using nested primers to increase sensitivity resulted in CK19 mRNA being detected after two amplification rounds in blood from healthy volunteers.

show abstract

Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.

Cited by 248 publications

References 22 publications

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases

Putative markers for the detection of breast carcinoma cells in blood

Contact Info

Product

Resources

About